Morris Matthew Shawn Buys Significant Stake in PRVA

Morris Matthew Shawn made a notable insider purchase of PRVA shares, buying 88,110 shares at a price of $2.00 each. This transaction, completed on June 26, 2026, is valued at $176,220.

Insider Buying and Selling at Privia Health Group, Inc.

Morris Matthew Shawn has been actively trading PRVA shares, with recent transactions including a buy of 88,110 shares on June 26, 2026, at $2.00 per share. Other insider activity includes David Mountcastle, EVP & Chief Financial Officer, who bought 17,196 shares at the same price on the same day.

Other Institutional Activity in PRVA

Institutional activity around PRVA has been lively. BlackRock, Inc. increased its holdings by 93,747 shares, reaching a total of 19,057,910 shares valued at approximately $392.0 million, marking a 0.5% increase. FMR LLC added 995,493 shares, a significant 8.3% increase, bringing its total to 13,045,542 shares worth around $268.3 million. Vanguard Portfolio Management LLC opened a new position with 6,281,542 shares valued at $129.2 million. Meanwhile, Rubicon Founders LLC grew its stake by 175,142 shares, a 3.0% increase, to 5,948,664 shares valued at $122.4 million.

Privia Health Group, Inc. Stock Up 24.7%

Shares of PRVA traded near $25.55 on Wednesday. The stock has drawn attention from several large institutional investors, reflecting confidence in its potential. Analyst ratings remain mixed, with Barclays maintaining a 'hold' rating and a $24 target, while others like Canaccord Genuity continue to recommend a 'buy', setting targets as high as $34.

Analysts Set New Price Targets

On May 26, 2026, Barclays maintained its 'hold' rating on PRVA with a price target of $24. Canaccord Genuity kept a 'buy' rating with a target of $34 on May 8, 2026. Evercore ISI Group also maintained a 'buy' rating with a $26 target on April 8, 2026. The consensus among analysts suggests a positive outlook with a mean target price of $32.

About PRVA

PRVA operates in the healthcare sector, providing a variety of services aimed at improving patient care and operational efficiency. The company is involved in innovative healthcare solutions and is headquartered in the United States. Its focus on patient-centric approaches has positioned it as a key player in the industry.

Bottom Line

Morris Matthew Shawn's insider purchase of PRVA shares highlights significant insider confidence in the company. Institutional investors have shown increased interest, with notable firms expanding their positions. Analysts maintain a generally positive outlook, with several recommending a 'buy'. As always, 13F filings and insider transactions are backward-looking and may not reflect current positions.